Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;26(9):1177.
doi: 10.18553/jmcp.2020.26.9.1177.

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis

Ronald Preblick  1 , Cori Gray  1 , Talaha Ali  1 , Pronabesh DasMahapatra  1
Affiliations
Comment

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis

Ronald Preblick et al. J Manag Care Spec Pharm. 2020 Sep.

Abstract

No funding supported the writing of this letter. Preblick, Ali, and DasMahapatra are employees and shareholders of Sanofi Genzyme. Gray is a postdoctoral fellow at Sanofi Genzyme and Rutgers University.

PubMed Disclaimer

Conflict of interest statement

No funding supported the writing of this letter. Preblick, Ali, and DasMahapatra are employees and shareholders of Sanofi Genzyme. Gray is a postdoctoral fellow at Sanofi Genzyme and Rutgers University.

Comment in

  • The Authors Respond.
    Simpson ML, Desai V, Maro GS, Yan S. Simpson ML, et al. J Manag Care Spec Pharm. 2020 Sep;26(9):1177-1178. doi: 10.18553/jmcp.2020.26.9.1177a. J Manag Care Spec Pharm. 2020. PMID: 32857661 Free PMC article.

Comment on

References

    1. Simpson ML, Desai V, Maro GS, Yan S. Comparing factor use and bleed rates in U.S. hemophilia A patients receiving prophylaxis with 3 different long-acting recombinant factor VIII products. J Manag Care Spec Pharm. 2020;26(4):504-12. - PMC - PubMed
    1. Mahlangu J, Young G, Hermans C, et al. . Defining extended half-life rFVIII – a critical review of the evidence. Haemophilia. 2018;24(3):348-58. - PubMed
    1. Lambert T, Benson G, Dolan G, et al. . Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295-308. - PMC - PubMed
    1. Bladen M, Main E, Hubert N, et al. . Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia. Haemophilia. 2013;19(4):626-31. - PubMed
    1. Oldenburg J, Hay CRM, Jimenez-Yuste V, et al. . Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open. 2019;9:3028012. - PMC - PubMed